Results 71 to 80 of about 36,355 (226)

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

open access: yesActa Psychiatrica Scandinavica, EarlyView.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian   +3 more
wiley   +1 more source

Association between early ondansetron use and the risk of sepsis in intensive care unit patients: a secondary data of the Medical Information Mart for Intensive Care IV database

open access: yesBMJ Open
Objective This study planned to analyse the association between ondansetron use within 24 hours before intensive care unit (ICU) admission to within 48 hours after ICU admission and the risk of sepsis in ICU patients.Design A cohort study.Setting and ...
Xuan Liu, Qiuye Kou, Enhe Liu
doaj   +1 more source

Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. [PDF]

open access: yes, 2016
Opioid use in pregnancy has increased dramatically over the past decade. Since prenatal opioid use is associated with numerous obstetrical and neonatal complications, this now has become a major public health problem.
Davis, Jonathan M.   +2 more
core   +2 more sources

Intravenous methadone for pain management in cardiac surgery: a randomised controlled trial with plasma concentration analysis*

open access: yesAnaesthesia, EarlyView.
Summary Introduction Postoperative pain after cardiac surgery remains significant despite the administration of opioids. Methadone may improve pain control and decrease the need for postoperative opioids. Randomised controlled trials, however, are limited and the effects of cardiopulmonary bypass on methadone pharmacokinetics are unclear.
Henry Man Kin Wong   +8 more
wiley   +1 more source

Humphrey Center News: Spring 1991 v. 6, no. 1 [PDF]

open access: yes, 1991
Newsletter of the Hubert H.
Anthony, Richard P.   +1 more
core  

Involvement of N-methyl-d-aspartate receptors in the antidepressant-like effect of 5-hydroxytryptamine 3 antagonists in mouse forced swimming test and tail suspension test. [PDF]

open access: yes, 2016
Recent evidence indicates that 5-hydroxytryptamine 3 (5-HT3) antagonists such as ondansetron and tropisetron exert positive behavioral effects in animal models of depression. Due to the ionotropic nature of 5-HT3 and N-methyl-d-aspartate (NMDA) receptors,
Amini-Khoei, Hossein.   +5 more
core   +1 more source

Clinical guidelines highlight for the hospitalist: Management of cyclic vomiting syndrome in children

open access: yes
Journal of Hospital Medicine, EarlyView.
Yamileth N. Hernandez, Hannah M. Gardner
wiley   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

open access: yesBritish Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan   +2 more
wiley   +1 more source

Ondansetron does not inhibit the analgesic effect of alfentanil [PDF]

open access: yes, 2017
5-Hydroxytryptamine (5-HT) causes antinociception via presynaptic 5-HT3 (5-HT subtype 3) receptors on primary afferent nociceptive neurones in the spinal cord dorsal horn.
ARENDT-NIELSEN, L.   +6 more
core  

Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People

open access: yesJournal of the American Geriatrics Society, EarlyView.
This graphical abstract illustrates the annual prevalence of exposure to CPIC Level A drugs among older adults, categorized by type of pharmacogenetic recommendation. Data are presented per 1000 older individuals (A) and per 1000 prescriptions (B).
Zinan Zhao   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy